Bioengineered <i>Escherichia coli</i> Nissle 1917 for tumour‐targeting therapy

Yu, Xiaoli; Lin, Changsen; Yu, Jing; Qi, Qingsheng; Wang, Qian

doi:10.1111/1751-7915.13523

Cited by 90 publications

(65 citation statements)

References 65 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another mechanism through which esophageal microbiota may play a therapeutic role in the EAC cascade is through the bioengineered Escherichia coli Nissle 1917 [ 126 ]. It is capable of acting as a probiotic as well as producing and delivering antitumor treatment.…”

Section: Therapeutic Potential Of Esophageal Microbiotamentioning

confidence: 99%

“…In colitis, Escherichia coli Nissle 1917 has been shown to positively affect microbiota balance and induce and maintain ulcerative colitis remission [ 127 ]. The potential therapeutic effect of Escherichia coli Nissle 1917 has not been analyzed in the EAC cascade at this point in time, however it certainly can be a target for future research [ 126 ].…”

Section: Therapeutic Potential Of Esophageal Microbiotamentioning

confidence: 99%

See 1 more Smart Citation

The Role of Microbiota in the Pathogenesis of Esophageal Adenocarcinoma

Gillespie

Rai

Agrawal

et al. 2021

Biology

View full text Add to dashboard Cite

Esophageal adenocarcinoma (EAC) is associated with poor overall five-year survival. The incidence of esophageal cancer is on the rise, especially in Western societies, and the pathophysiologic mechanisms by which EAC develops are of extreme interest. Several studies have proposed that the esophageal microbiome may play an important role in the pathophysiology of EAC, as well as its precursors—gastroesophageal reflux disease (GERD) and Barrett’s esophagus (BE). Gastrointestinal microbiomes altered by inflammatory states have been shown to mediate tumorigenesis directly and are now being considered as novel targets for both cancer treatment and prevention. Elucidating molecular mechanisms through which the esophageal microbiome potentiates the development of GERD, BE, and EAC will provide a foundation on which new therapeutic targets can be developed. This review summarizes current findings that elucidate the molecular mechanisms by which microbiota promote the pathogenesis of GERD, BE, and EAC, revealing potential directions for additional research on the microbiome-mediated pathophysiology of EAC.

show abstract

Section: Therapeutic Potential Of Esophageal Microbiotamentioning

confidence: 99%

Section: Therapeutic Potential Of Esophageal Microbiotamentioning

confidence: 99%

The Role of Microbiota in the Pathogenesis of Esophageal Adenocarcinoma

Gillespie

Rai

Agrawal

et al. 2021

Biology

View full text Add to dashboard Cite

show abstract

“…Different genetically programmed bacteria that can express luciferase have been widely used for real‐time in vivo imaging of tumors. Among these bacteria, tumor therapy using Salmonella and EcN have shown promising results (X. Yu et al, 2020).…”

Section: Bacteria‐mediated Cancer Therapy (Bmct)mentioning

confidence: 99%

The potential use of theranostic bacteria in cancer

Azizian

Pustokhina

Ghanavati³

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Conventional chemotherapy approaches have not been fully successful in the treatment of cancer, due to limitations imposed by the pathophysiology of solid tumors, leading to nonspecific drug uptake by healthy cells, poor bioavailability, and toxicity. Thus, novel therapeutic modalities for more efficient cancer treatment are urgently required. Living bacteria can be used as a theranostic approach for the simultaneous diagnosis and therapy of tumors. Herein, we summarize the currently available literature focused on the advantages and challenges for the use of theranostic bacteria in cancer therapy.

show abstract

“…While the hypoxic TME represents a primary barrier to RT treatment, it is also an ideal habitat for certain species of anaerobic bacteria and facultative anaerobes. [ 13 ] Indeed, several species of Salmonella , [ 14 ] Bifid bacterium , [ 15 ] Clostridium , [ 16 ] and Escherichia coli ( E. coli ) [ 17 ] have been found to exhibit a hypoxic tropism and to readily accumulate and replicate within tumor sites. These highly targeted bacteria are thus ideal for the targeted treatment of hypoxic tumors.…”

Section: Introductionmentioning

confidence: 99%

Hypoxic Tumor Radiosensitization Using Engineered Probiotics

Huang

Wang

Liu

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Owing to their ability to rapidly proliferate in specific niches and their amenability to genetic manipulation, bacteria are frequently studied as potential diagnostic or therapeutic bioagents in a range of pathological contexts. A sustained oxygen supply within solid tumors is essential in order to achieve positive radiotherapy (RT) outcomes, as these intratumoral oxygen levels are necessary to facilitate RT-induced reactive oxygen species (ROS) generation. In this study, a genetically engineered variant of the tumor-targeting probiotic E. coli Nissle 1917 bacteria that secret catalase is utilized to alleviate intratumoral hypoxia and to thereby enhance tumor radiosensitivity. These engineered bacteria are able to facilitate robust O 2 evolution and consequent ROS generation in response to X-ray irradiation both in vitro and in vivo, significantly inhibiting tumor growth. Overall, the study highlights a novel and practical approach to enhance the efficacy of tumor RT, underscoring the value of future research in the field of probiotic medicine.

show abstract

Bioengineered Escherichia coli Nissle 1917 for tumour‐targeting therapy

Cited by 90 publications

References 65 publications

The Role of Microbiota in the Pathogenesis of Esophageal Adenocarcinoma

The Role of Microbiota in the Pathogenesis of Esophageal Adenocarcinoma

The potential use of theranostic bacteria in cancer

Hypoxic Tumor Radiosensitization Using Engineered Probiotics

Contact Info

Product

Resources

About